Patients want to talk about their out-of-pocket costs-Can real-time benefit tools help?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Integrating Out-of-Pocket Costs Into Shared Decision-Making for Heart Failure With Reduced Ejection Fraction: A Stepped-Wedge Trial (POCKET-COST-HF).Circulation. Cardiovascular quality and outcomes · 2025
   Trial
2. Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity.Current atherosclerosis reports · 2023
   Review

Corrections and comments

• Comment on
  "Worth it if you could afford it": Patient perspectives on integrating real-time benefit tools into drug cost conversations.2023

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as